NewsBenzinga카르테시안 테라퓨틱스, 2026년 AANEM 연례 학술대회 MGFA 세션에서 범형 MG 환자 대상 주요 임상 자산 데카르트-08의 추가 재치료 데이터 발표 카르테시안 테라퓨틱스, 2026년 AANEM 연례 학술대회 MGFA 세션에서 범형 MG 환자 대상 주요 임상 자산 데카르트-08의 추가 재치료 데이터 발표 Benzinga 2026.09.29 11:32 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
